Evidence map›Paper›PMID 37653513›Full record

Trial reportBMC medical imaging2023

Multiparametric MRI radiomics for the differentiation of brain glial cell hyperplasia from low-grade glioma.

Siqian Gu, Jing Qian, Ling Yang, Zhilei Sun, Chunhong Hu, Ximing Wang, Su Hu, Yuyang Xie

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC medical imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Siqian GuDepartment of Radiology, The First Affiliated Hosptial of Soochow University, 215006, Suzhou, China.
Jing QianDepartment of Radiology, The First Affiliated Hosptial of Soochow University, 215006, Suzhou, China.
Ling YangDepartment of Radiology, The First Affiliated Hosptial of Soochow University, 215006, Suzhou, China. ylsuzhoucanglang@163.com.
Zhilei SunDepartment of Radiology, The First Affiliated Hosptial of Soochow University, 215006, Suzhou, China.
Chunhong HuDepartment of Radiology, The First Affiliated Hosptial of Soochow University, 215006, Suzhou, China.
Ximing WangDepartment of Radiology, The First Affiliated Hosptial of Soochow University, 215006, Suzhou, China.
Su HuDepartment of Radiology, The First Affiliated Hosptial of Soochow University, 215006, Suzhou, China.
Yuyang XieSoochow University, 215006, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferentiating between low-grade glioma and brain glial cell hyperplasia is crucial for the customized clinical treatment of patients.

objectiveBased on multiparametric MRI imaging and clinical risk factors, a radiomics-clinical model and nomogram were constructed for the distinction of brain glial cell hyperplasia from low-grade glioma.

methodsPatients with brain glial cell hyperplasia and low-grade glioma who underwent surgery at the First Affiliated Hospital of Soochow University from March 2016 to March 2022 were retrospectively included. In this study, A total of 41 patients of brain glial cell hyperplasia and 87 patients of low-grade glioma were divided into training group and validation group randomly at a ratio of 7:3. Radiomics features were extracted from T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), contrast-enhanced T1-weighted imaging (T1-enhanced). Then, LASSO, SVM, and RF models were created in order to choose a model with a greater level of efficiency for calculating each patient's Rad-score (radiomics score). The independent risk factors were identified via univariate and multivariate logistic regression analysis to filter the Rad-score and clinical risk variables in turn. A radiomics-clinical model was next built of which effectiveness was assessed.

resultsBrain glial cell hyperplasia and low-grade gliomas from the 128 cases were randomly divided into 10 groups, of which 7 served as training group and 3 as validation group. The mass effect and Rad-score were two independent risk variables used in the construction of the radiomics-clinical model, and their respective AUCs for the training group and validation group were 0.847 and 0.858. The diagnostic accuracy, sensitivity, and specificity of the validation group were 0.821, 0.750, and 0.852 respectively.

conclusionCombining with radiomics constructed by multiparametric MRI images and clinical features, the radiomics-clinical model and nomogram that were developed to distinguish between brain glial cell hyperplasia and low-grade glioma had a good performance.

Indexed as

GliomaMultiparametric Magnetic Resonance ImagingBrainCell DifferentiationHumansHyperplasiaNeurogliaRetrospective StudiesBrain glial cell hyperplasiaLow-grade gliomaMultiparametric MRI imagesRadiomics

Identifiers

PMID37653513
PMCPMC10472728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.